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ABSTRACT  27 
The thiazide-sensitive NaCl cotransporter (NCC) is an important pharmacological target in 28 
the treatment of hypertension. Human SLC12A3 gene, encoding NCC, gives rise to three 29 
isoforms. Only the 3rd isoform has been extensively investigated. The aim of the present 30 
study was, therefore, to establish the abundance and localization of the almost identical 31 
isoforms 1 and 2 (NCC1/2) in the human kidney and to determine their functional properties 32 
and regulation in physiological conditions. Immunohistochemical analysis of NCC1/2 in the 33 
human kidney revealed that NCC1/2 localizes to the apical plasma membrane of the distal 34 
convoluted tubule. Importantly, NCC1/2 mRNA constitutes approximately 44% of all NCC 35 
isoforms in the human kidney. Functional analysis performed in the Xenopus laevis oocyte 36 
revealed that thiazide-sensitive 22Na+ transport of NCC1 was significantly increased in 37 
comparison to NCC3. Mimicking a constitutively active phosphorylation site at residue 811 38 
(S811D) in NCC1 further augmented Na+ transport, while a non-phosphorylatable variant 39 
(S811A) of NCC1 prevented this enhanced response. Analysis of human urinary exosomes 40 
demonstrated that water loading in human subjects significantly reduces the abundance of 41 
NCC1/2 in urinary exosomes. The present study highlights that previously 42 
underrepresented NCC1/2 is a fully functional thiazide-sensitive NaCl-transporting protein. 43 
Being significantly expressed in the kidney it may constitute a unique route of renal NaCl 44 
reabsorption and could, therefore, play an important role in blood pressure regulation.  45 
 46 
INTRODUCTION 47 
Hypertension is a global disease with an overall prevalence around 30-45% in the general 48 
population (18, 21). The kidneys play a key role in chronic blood pressure homeostasis by 49 
maintaining appropriate renal salt reabsorption. It is of critical importance to understand the 50 
molecular mechanisms governing renal NaCl transport in physiological and 51 
pathophysiological conditions in order to exploit them as therapeutic targets. 52 
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 53 
The 2014 evidence-based guideline for the management of high blood pressure in adults 54 
recommends thiazide-type diuretics as initial therapy for hypertension (18). Thiazide-type 55 
diuretics act by blocking the NaCl cotransporter (NCC) in the distal convoluted tubule 56 
(DCT), highlighting the importance of NCC in blood pressure regulation. Mutations in NCC-57 
encoding gene (SLC12A3) cause Gitelman’s syndrome (OMIM 263800), a condition 58 
characterized by salt wasting and hypotension (13, 22). A mirror image of Gitelman’s 59 
syndrome with increased renal reabsorption of NaCl and a resultant increase in systemic 60 
blood pressure can be observed in patients with Pseudohypoaldosteronism type II (PHAII, 61 
also known as Gordon syndrome (OMIM 145260) (10). PHAII results from mutations in the 62 
WNK [with-no-K(Lys)] kinases (members WNK1 and WNK4) (47), as well as kelch-like 3 63 
(KLHL3) and cullin 3 (CUL3) (2, 14), which play an instrumental role in regulating NaCl 64 
reabsorption in the distal part of the nephron (20, 29, 31, 45, 47, 48). The amino- (N)-65 
terminal domain of NCC contains several phosphorylation sites being of critical importance 66 
for NCC function. These residues are targets of the serine-threonine kinases, Ste20-67 
related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1) (27, 68 
31). In addition, kinases in the WNK family as well as the serum- and glucocorticoid-69 
inducible kinase 1 (SGK1) interact within the network of SPAK and OSR1, thereby 70 
affecting the phosphorylation status of NCC (7, 38, 39, 49).  71 
 72 
The SLC12A3 gene encoding the human NCC yields three separate isoforms as a result 73 
of an alternative splicing. An mRNA sequence encoding a 1,030 amino acid NCC protein 74 
was first deposited in the GenBank by Simon et al. (35) representing isoform 1 (NCC1) 75 
(accession no. NP_000330.2). Subsequently, Mastroianni et al. (23) reported an mRNA 76 
sequence encoding a protein of 1,021 amino acids representing isoform 3 (NCC3) 77 
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(accession no. NP_001119580.1), in which exon 20 is nine amino acids shorter than in 78 
NCC1. Following studies confirmed the presence of both long and short form of the exon 79 
20 (20a and 20b respectively) as a result of a possible cryptic splicing donor site (22). 80 
Moreover, cDNA analysis indicated that NCC3 constitutes the predominant form in the 81 
human kidney (22). Isoform 2 (NCC2) (accession no. NP_001119579.1) is only one amino 82 
acid shorter than NCC1. Recently, Gonzales et al.(15) used a proteomic approach to 83 
analyze human urinary exosomes and identified a novel phosphorylation site at serine 84 
(Ser811). This residue is present only in NCC1 and NCC2. Interestingly, mouse and rat 85 
SLC12A3 genes do not contain the segment coded by human exon 20, hence NCC1 and 86 
NCC2 are not present in these animals. The lack of NCC1 and NCC2 in rodents hampered 87 
the progress and interest towards further investigations and until now NCC3 has 88 
predominantly been studied (8, 12). At present, detailed localization of NCC1 and NCC2 89 
proteins in human kidney, their regulatory network, and relevance in renal Na+ handling 90 
remain to be elucidated.  91 
 92 
The goal of the present study was, therefore, to determine the abundance and localization 93 
of previously underrepresented NCC isoforms in comparison to NCC3 in the human kidney 94 
as well as their functional properties and regulation in physiological conditions. To this end, 95 
the presence of NCC1, NCC2, and NCC3 in the human urinary exosomes was assessed by 96 
mass spectrometric analysis. The localization and regulation of NCC isoforms was 97 
investigated by immunohistochemical analysis in human kidney biopsies and by 98 
immunoblotting of kidney membrane fractions and urinary exosomes with newly developed 99 
isoform specific antibodies. Functional capacity to transport Na+ by NCC1 was determined 100 
using the Xenopus oocytes expression system. Furthermore, to evaluate physiological 101 
regulation of NCC isoforms during acute water loading of human subjects was chosen as a 102 
model, since hormones maintaining water balance are known to regulate NCC (5, 28, 30-103 
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34, 41, 42).  104 
 105 
MATERIALS AND METHODS  106 
Isolation and sequencing of NCC variants from human kidney 107 
Human kidney cDNA was amplified using primers against the C-terminal domain of NCC. 108 
The PCR product was isolated, cloned into the pGEM®-T Easy Vector System (Promega), 109 
and transformed into DH5-E. Coli bacteria. Colonies were isolated, plasmid DNA was 110 
extracted, and submitted for Sanger sequencing. The resulting chromatograms from the 111 
sequencing confirmed the presence of NCC1/2 and NCC3 in the human kidney.  112 
 113 
Real-time relative RT-PCR quantification  114 
All 7 donors gave permission for donating their kidneys after death. In case the kidney 115 
appeared not suitable for transplantation the donor gave permission to use the kidneys for 116 
research purposes, which is registered in the Dutch Donor registry. Relative amount of 117 
NCC1/2 and NCC1-3 mRNA in the human kidney was determined by a real-time RT-PCR 118 
based on the standard curve method (46). RNA from 7 healthy humans kidney cortex was 119 
isolated with Trizol Reagent (Life Technologies, Grand Island, NY, USA) and cDNA was 120 
synthesized with moloney murine leukemia virus (M-MLV) revers transcriptase (Invitrogen, 121 
Grand Island, NY, USA). Following primers amplifying specifically NCC1/2 as well as 122 
primers against N-terminal fragment recognizing both NCC1/2 and NCC3 combined (NCC1-123 
3) were used: NCC1/2 Fw: GTGCCAGGCCATCAGTCT; NCC1/2 Rev: 124 
TATGGTCTTCTTGCCCTGCT; NCC1-3 Fw: TGTTTGGGGCTATCATCTCC; NCC1-3 Rev:  125 
GAGGAGCCCCAATTTACCTC. Standard curve was prepared based on mixed DNA 126 
plasmids containing both NCC1/2 and NCC3 dilutions ranging from 2.5 × 105 – 5.12 × 108. 127 
Quantification was performed with iQ SYBR Green supermix system (Bio-Rad, Hercules, 128 
Splice variant of the NaCl cotransporter 
6 
CA, USA) according to manufacturer’s instructions. The products of the RT-PCR were 129 
verified by sequencing. The absolute copy number per µg of mRNA isolated form the 130 
human cortex was defined and the ratio of NCC1/2 to NCC1-3 was determined.   131 
 132 
Mutagenesis and constructs 133 
Human NCC in pT7Ts has been previously described.(7) The human NCC1 fragment was 134 
generated by site directed mutagenesis using the QuikChange site-directed mutagenesis 135 
kit (Stratagene, La Jolla, CA, USA) with the following primers: Fw 136 
GCGCCAGAGGTGCCAGGCCATCAGTCTCTGGCGCTTTGGACCCCAAGGC; Rev: 137 
GCCTTGGGGTCCAAAGCGCCAGAGACTGATGGCCTGGCACCTCTGGCGC; and 138 
subsequently inserted in the NCC3-pT7Ts. The NCC1 phosphomutants mimicking the 139 
active (S811D) and the inactive (S811A) phosphorylation sites were generated by site 140 
directed mutagenesis. Primers: S811D Fw: GTGCCAGGCCAGACGTCTCTGGCGCTTTG; 141 
Rev: CAAAGCGCCAGAGACGTCTGGCCTGGCAC; S811A Fw: 142 
GTGCCAGGCCAGCAGTCTCTGGCGCTTTG; Rev: 143 
CAAAGCGCCAGAGACTGCTGGCCTGGCAC. eGFP-NCC in pT7Ts was described 144 
previously.(7) The C-terminal part of human NCC1 in pT7Ts was subcloned into the eGFP-145 
NCC construct. For expression in mammalian systems, human eGFP-NCC3 fragment 146 
described previously(7) was subcloned into empty pCMV-SPORT6 vector. Human NCC1 147 
and NCC1 phosphorylation site mutants (S811A and S811D) fragments were subcloned to 148 
eGFP-NCC3 pCMV SPORT6 construct. All the constructs were confirmed by sequence 149 
analyses. 150 
 151 
In vitro cRNA translation for functional assays 152 
Microinjection of cRNA and 22Na+ uptake experiments were performed essentially as 153 
described previously (7). Briefly, constructs encoding the NCC variants were linearized, 154 
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transcribed in vitro using the mMESSAGE mMACHINE® T7 Kit (Ambion, Austin, TX, USA). 155 
The integrity of the product was confirmed on 1% w/v agarose, 37% v/v formaldehyde gels 156 
and cRNA aliquots were stored at –80°C. 157 
 158 
Oocyte harvesting and animal experimentation  159 
All animal experiments received the approval from the animal ethics board of Radboud 160 
university medical center, Nijmegen, The Netherlands. Xenopus laevis oocytes were 161 
processed based on previous established protocols (7). Mature oocytes were selected and 162 
microinjected with 5 ng of cRNA encoding the human NCC1, NCC3, NCC1 S811D, NCC1 163 
S811A or co-injected with 10 ng of WNK4 cRNA. 22Na+ uptake was corrected for the 164 
surface expression of the corresponding microinjected variant and expressed as a percent 165 
of WT uptake. All the experiments using 22Na+ radioisotope were approved and monitored 166 
by the Environmental Health and Radiation Safety office, Radboud university medical 167 
center. 168 
 169 
Quantification of eGFP-NCC in the oocyte membrane  170 
Surface expression analyses were performed as described in detail previously (7). Briefly, 171 
oocytes were microinjected with 5 ng of cRNA encoding eGFP-NCC1, eGFP-NCC3, or 172 
eGFP-NCC1 phosphorylation site mutants. All images were acquired on an Olympus 173 
FV1000 laser-scanning microscope (Center Valley, PA, USA) using a 10 x water objective. 174 
Densitometry analysis of fluorescence was done using Image J software (image 175 
processing program, NIH, Bethesda, MA, USA). Autofluorescence of water-injected 176 
oocytes was subtracted from the fluorescence of all injected variants. 177 
 178 
Cell culture, transfection, and isolation of enriched plasma membrane 179 
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HEK293 cells were cultured on 100 mm dishes and grown in DMEM supplemented with 180 
10% v/v fetal bovine serum, nonessential amino acids, and 2 mM L-glutamine. Cells were 181 
transfected with eGFP-NCC3 pCMV SPORT6, eGFP-NCC1 pCMV SPORT6, eGFP-NCC1 182 
S811D pCMV SPORT6 and eGFP-NCC1 S811A pCMV SPORT6 vector using 32 μg of 183 
DNA and 96 μl of polyethylenimine (Polysciences, Inc., Warrington, PA, USA). Cells 184 
transfected with empty vector were used as controls (mock). At 48 hours post-transfection 185 
the cells were lysed in 1 ml of ice-cold dissection buffer per dish (300 mM sucrose, 25 mM 186 
imidazole, 1 mM EDTA, 1 μg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 187 
μg/ml leupeptin and 5 μg/ml apropotin). Lysed cells were centrifuged at 4,000 x g for 8 188 
minutes and subsequently the supernatant was centrifuged at 16,000 x g for 40 minutes. 189 
The pellet was resuspended in ice-cold dissection buffer and 1x Laemmli (0.4% w/v SDS, 190 
2% v/v glycerol, 12 mM Tris-HCl pH 6.8, 40 mM DTT and 0.002% w/v bromophenol blue) 191 
was added. Samples were incubated in 65°C for 15 minutes. BCA Protein Assay Kit 192 
(Pierce, Thermo Scientific, Rockford, IL, USA) was used to determine the protein 193 
concentration. 194 
 195 
Kidney membrane preparations for NCC immunoblots 196 
All three donors gave permission for donating their kidneys after death. In case the kidney 197 
appeared not suitable for transplantation the donor gave permission to use the kidneys for 198 
research purposes, which is registered in the Dutch Donor registry. Harvested kidneys 199 
were snap-frozen immediately after isolation and homogenized in detergent-free lysis 200 
buffer containing 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM sodium 201 
orthovanadate, 5 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 202 
0.1% v/v 2-mercaptoethanol and protease inhibitors (Roche, 1 tablet per 50 ml) with a 203 
homogenizer (VWR VDI 12 Adaptable Homogenizers, OpticsPlanet, Inc., Commercial 204 
Avenue Northbrook, IL, USA). Nuclei and debris were pelleted by centrifugation at 1,500 x 205 
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g for 5 minutes at 4°C. Next, supernatants were centrifuged at 100,000 x g for 1 hour at 206 
4°C. The pellet was washed with 1 vol. of lysis buffer without reducing agent and 207 
centrifuged again at 100,000 x g for 15 minutes to remove any remaining cytosolic 208 
particles. The pellet was then resuspended in lysis buffer including 1% v/v Nonidet P40. 209 
BCA Protein Assay Kit (Pierce, Thermo Scientific, Rockford, IL, USA) was used to 210 
determine the protein concentration. Finally, samples were stored at -80°C for the 211 
immunoblotting. 212 
 213 
Immunoblotting  214 
Exosome and kidney membrane samples were loaded on a gradient SDS-PAGE gel (4-215 
15% v/v Criterion™ TGX™ Precast Gel, Bio-Rad, The Netherlands) and cell membrane 216 
proteins (10 μg) were loaded on an 8% v/v SDS-PAGE gel. Proteins were transferred to 217 
PVDF membranes (Immobilon-P, Millipore Corporation, Bedford, MA, USA) by 218 
electroelution. PVDF membranes were incubated for 16 hours with primary antibodies in 219 
4°C, washed and subsequently incubated with secondary antibody for two hours in room 220 
temperature. Proteins were visualized using enhanced chemiluminescence (Thermo 221 
Fischer Scientific, Waltham, MA, USA) and a gel imaging system (ChemiDoc XRS, Bio-222 
Rad Laboratories, Hercules, CA, USA). Densitometry was performed using Image J 223 
software (image processing program, NIH, Bethesda, MA, USA). 224 
 225 
Immunohistochemistry 226 
Immunohistochemical staining was performed on cryosections of snap-frozen tissue. 227 
Briefly, 2 μm serial sections of frozen human kidney were fixed with acetone for 10 228 
minutes at -20°C. The sections were incubated for 1 hour at room temperature with 229 
primary antibody diluted in TNB buffer (0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.5% w/v, 230 
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Blocking Reagent, #FP1020, Perkin Elmer, Groningen, The Netherlands). For detection, 231 
kidney sections were incubated with Alexa flour-conjugated secondary antibodies. Images 232 
were taken with an Axio Imager camera and ZEN Lite software (Zeiss, Sliedrecht, The 233 
Netherlands). 234 
 235 
Antibodies 236 
Anti NCC1/2 rabbit polyclonal antibody was manufactured by 21st Century Biochemicals 237 
(Marlborough, MA, USA).  Briefly, peptide corresponding to the sequence NH2-238 
ARGARPSVSGALDP-COOH was manufactured by Fmoc chemistry and after 239 
cleavage/deprotection was HPLC purified to >90%, and the mass and sequence verified 240 
by nanospray MS and CID MS/MS, respectively.  This peptide was conjugated to carrier 241 
protein and used to immunize two New Zealand rabbits.  After multiple boosts and bleeds, 242 
the serum was immunodepleted by affinity purification of the antibody specific to NCC1/2 243 
with affinity column containing the immunizing peptide. The antibody was used at the 244 
following dilution rates: IB 1:1,000, IHC 1:50. Rabbit polyclonal antibody against the N-245 
terminal portion of rat NCC (Millipore, Billerica, MA, USA, #AB3553; IB 1:2,000, IHC 1:50). 246 
Rabbit polyclonal antibody against rat (R7) AQP2 (kindly provided by Dr. Peter Deen; IB 247 
1:3,000).(6) Mouse monoclonal antibody against amino acids 101-210 of CD9 of human 248 
origin (C4, Santa Cruz Biotechnology, Inc., CA, USA; IB 1:500). Secondary antibodies 249 
were as follows: peroxidase conjugated goat anti-rabbit (Sigma-Aldrich, St. Luis, MO, 250 
USA, #A4914; IB 1:10,000), goat anti-rabbit Alexa Fluor® 488 (Molecular Probes, Eugene, 251 
OR, USA, #A-11029, IHC 1:300). 252 
 253 
Acute water loading 254 
The study was conducted according to the principles expressed in the declaration of 255 
Helsinki. All participants gave written informed consent and the study protocol was 256 
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approved by the Institutional Review Board of the Radboud university medical center, 257 
Nijmegen, The Netherlands (approval number NL47178.091.13). Healthy males between 258 
25 to 35 years old and with a body weight below 100 kg body weight were included in the 259 
study. Subjects were asked to refrain from coffee, tea, alcohol intake and any vigorous 260 
exercise for 24 hours before and during the study. Subjects did not drink or eat for 12 261 
hours before the first urine collection to achieve maximal urine concentration. Each subject 262 
ingested 20 ml/kg body weight of water in 30 minutes. Midstream urine was collected 263 
before (time 0 minutes) and after water ingestion in 30 minutes intervals up to 150 264 
minutes. Collected urine samples were supplemented with a final concentrations of 265 
protease inhibitors of 50 µM phenylmethylsulfonyl (PMSF), 20 µM aprotinin, 10 µM 266 
pepstatin A, 20 µM leupeptin, and stored at -80°C. 267 
 268 
Urinary exosome isolation 269 
The urine samples were collected from healthy subjects after acute water loading (see 270 
Supplement). Ten ml of collected urine was centrifuged at 17,000 × g for 15 minutes at 271 
24°C in ultracentrifuge (Sorvall™ WX Floor Ultra Centrifuges, Thermo Scientific, Asheville, 272 
NC, USA) with 70.1Ti rotor. Supernatant was stored at room temperature for 25 minutes. 273 
The pellet was resuspended in 200 μl isolation solution (250 mM sucrose and 10 mM 274 
triethanolamine-HCl, pH 7.6) and 50 μl 3.24 M dithiothreitol (DTT), subsequently 275 
centrifuged at 17,000 × g for 15 minutes at 24°C. Thereafter, the supernatant was 276 
collected, combined with supernatant obtained from the previous step and centrifuged at 277 
200,000 × g for 2 hours at 24°C. Exosome pellet was dissolved in 50 µl of 1.5 × Laemmli 278 
(0.6% w/v SDS, 3% v/v glycerol, 18 mM Tris-HCl pH 6.8 and 0.003% w/v bromophenol 279 
blue). All the samples were stored in -20°C for further use. 280 
 281 
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Mass spectrometry 282 
Gel slices were cut from the Coomassie-stained and washed SDS PAGE gel on a clean 283 
glass plate and were further diced in 1 mm3 cubes using a scalpel and were transferred to 284 
a 1.5 ml reaction tube for further processing. ¼ gelband equivalent was processed for 285 
trypsin digestion and ¾ gelband was processed for Lys-C digestion. Gel cubes were 286 
vortexed in 400 µl 50 mM NH4HCO3 for 10 minutes. Supernatant was removed and the gel 287 
cubes were vortexed in 400 µl 50 mM NH4HCO3, 50% v/v acetonitrile for 10 minutes. After 288 
removal of the supernatant this wash-step was repeated once. Gel cubes were reduced in 289 
10 mM DTT in 50 mM NH4HCO3 at 56°C in a heating block for 60 minutes. After cooling 290 
down the supernatant was removed and gel cubes were alkylated with 54 mM 291 
iodoacetamide in 50 mM NH4HCO3 for 45 minutes in the dark at RT. Supernatant was 292 
removed and gel cubes were vortexed in 400 µl 50 mM NH4HCO3 for 10 minutes. 293 
Supernatant was removed and the gel cubes were vortexed in 50 mM NH4HCO3/50% v/v 294 
acetonitrile. After removal of the supernatant this wash-step was repeated once. 295 
Supernatant was removed and gel cubes were dried in a vacuum centrifuge at 50°C for 10 296 
minutes. Dried gel slices were covered with trypsin solution or Lys-C solution (6.25 ng/µl in 297 
50 mM NH4HCO3), after rehydration of the cubes excess protease was removed and gel 298 
cubes were covered with 50 mM NH4HCO3. Digestion proceeded overnight at 25°C in a 299 
heating block. After digestion, peptides were extracted from the gel cubes with 100 µl 1% 300 
v/v formic acid by vortexing. Supernatant was transferred to a 1.5 ml tube and gel cubes 301 
were extracted with 100 µl 5% v/v formic acid 50% v/v acetonitrile. Supernatant was 302 
pooled with the first eluate. The second extraction was repeated once and the supernatant 303 
was pooled with previous extracts. Extracts were concentrated in a vacuum centrifuge at 304 
50°C and volumes were adjusted to 50 µl by adding 0.05% v/v formic acid. 305 
 306 
LC-MS/MS 307 
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Peptides were separated by an Ultimate 3000 nanoLC-MS/MS system (Dionex LC-308 
Packings, Amsterdam, The Netherlands) equipped with a 20 cm × 75 μm ID fused silica 309 
column custom packed with 1.9 μm 120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, 310 
Ammerbuch-Entringen, Germany). After injection (15/50 µl Lys-C digest; 20/50 µl trypsin 311 
digest), peptides were trapped at 6 μl/minute on a 10 mm × 100 μm ID trap column packed 312 
with 5 μm 120 Å ReproSil Pur C18 aqua at 2% buffer B (buffer A: 0.5% v/v acetic acid in 313 
MQ; buffer B: 80% v/v ACN + 0.5% v/v acetic acid in MQ) and separated at 300 nl/minute 314 
in a 10–40% buffer B gradient in 60 minutes (90 minutes inject-to-inject) at 50˚C. Eluting 315 
peptides were ionized at a potential of +2 kVa into a Q Exactive mass spectrometer 316 
(Thermo Fisher, Bremen, Germany). Intact masses were measured at resolution 70.000 317 
(at m/z 200) in the orbitrap using an AGC target value of 3 × 106 charges. The top 10 318 
peptides signals (charge-states 2+ and higher) were submitted to MS/MS in the HCD 319 
(higher-energy collision) cell (1.6 amu isolation width, 25% normalized collision energy). 320 
MS/MS spectra were acquired at resolution 17,500 (at m/z 200) in the orbitrap using an 321 
AGC target value of 1 × 106 charges, an underfill ratio of 0.1%, and a maximum injection 322 
time (IT) of 60 milliseconds. Dynamic exclusion was applied with a repeat count of 1 and 323 
an exclusion time of 30 seconds.   324 
 325 
Protein identification 326 
MS/MS spectra were searched against the Uniprot human reference proteome FASTA file, 327 
release January 2014, no fragments; 42104 entries using MaxQuant 1.5.2.8. Enzyme 328 
specificity was set to trypsin or Lys-C, depending on the protease used, and up to two 329 
missed cleavages were allowed. Cysteine carboxamidomethylation (Cys, +57.021464 Da) 330 
was treated as fixed modification and methionine oxidation (Met, +15.994915 Da), Gln-331 
>pyroglutamate (pyr-Gln, -17.026549 Da) and N-terminal acetylation (N-terminal, 332 
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+42.010565 Da) as variable modifications. Peptide precursor ions were searched with a 333 
maximum mass deviation of 4.5 ppm and fragment ions with a maximum mass deviation of 334 
20 ppm (default MaxQuant settings). Peptide and protein identifications were filtered at an 335 
FDR of 1% using the decoy database strategy. Proteins that could not be differentiated 336 
based on MS/MS spectra alone were grouped to protein groups (default MaxQuant 337 
settings).  338 
 339 
Measurement of urinary creatinine and osmolality. 340 
Urinary creatinine was measured according to Jaffe’s method with the use of colorimetric 341 
assay (Labor und Technik, Berlin, Germany).(37) Osmolality of urine samples was 342 
measured by freezing point depression using a Micro-osmometer  (Advanced Instrument 343 
model 3320, Nordwood, MA, USA). 344 
 345 
Statistical analysis  346 
In the oocyte analysis all depicted data are averages of at least 2 independent 347 
experiments, each containing a minimum of 10-15 oocytes per group. Overall statistics 348 
between groups was determined by one-way ANOVA. In case of significance, multiple 349 
comparisons between groups were performed by Bonferroni post-hoc tests. Immunoblot 350 
data were analyzed by comparing integrated optical densities of bands by one-way 351 
ANOVA followed by Dunnett's Multiple Comparison post-hoc test. Values are mean ± SEM 352 
in acute water loading: normalized to time 0 minutes levels, n = 6. For all experiments P 353 
value <0.05 was considered statistically significant. All the data were analyzed using Prism 354 
5 software (GraphPad Software Inc, La Jolla, CA, USA).  355 
 356 
RESULTS  357 
NCC splicing and the S811 phosphorylation site 358 
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Fig. 1A displays the protein sequence alignment encompassing the fragment specific for 359 
NCC1 and NCC2. NCC1 contains one extra amino acid as compared to NCC2, which is 360 
localized outside the exon 20 region. Therefore, NCC1/2 will refer to the combined 361 
presence of NCC1 and NCC2, as these are indistinguishable in several of the experimental 362 
assays performed in this study. The NCC1/2 is present and preserved between some 363 
mammalian species (human and rabbit), but is not present in rodents (mouse and rat). In 364 
humans, the NCC splice site is encoded by exon 20 (Fig. 1B). Remarkably, this exon is 365 
absent in mouse and rat due to the lack of splice sites. Fig. 1B shows the exon 366 
prearrangement of NCC1/2. Sequence analysis of cDNA fragments isolated from human 367 
kidney showed that both NCC1/2 and NCC3 are present (Fig. 1C). NCC1/2 is longer than 368 
NCC3 due to the presence of nine extra amino acid residues in the C-terminal domain (Fig. 369 
1D). The phosphorylation site identified in the additional fragment corresponds to residue 370 
S811 (Fig. 1D). Constructs encoding NCC3 and NCC1 as well as the phosphorylation site 371 
mutants (S811D and S811A) (Fig. 1D) were subcloned into appropriate plasmid vectors for 372 
heterologous expression in Human Embryonic Kidney (HEK293) cells and Xenopus laevis 373 
oocytes. Quantitative PCR analysis revealed that NCC1/2 mRNA constitute 44 ± 6% (n = 7) 374 
of all NCC isoforms present in the human kidney cortex biopsies (Table 1). 375 
 376 
Mass spectrometric identification of human NCC isoforms 377 
The presence of the NCC isoforms in the human urinary exosomes on the protein level 378 
was investigated by mass spectrometry. Data are available via ProteomeXchange with 379 
identifier PXD002279 (http://www.proteomexchange.org; Username: 380 
reviewer55274@ebi.ac.uk; Password: QI1g6xJe) (44). Overall 51 peptides were detected 381 
for SLC12A3 by tryptic digestion and 15 peptides by Lys-C digestion yielded sequence 382 
coverage of 14 and 39%, respectively. In Table 2 all identified SLC12A3 peptides are 383 
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summarized. Two regions in the amino-acid sequence allow distinction between the 384 
isoforms: Peptides correlated to V807L and 9 amino-acid deletion peptides indicating the 385 
presence of both NCC3 as well as NCC1/2 were identified. Isoform-specific peptides 386 
spanning residues 781-838 are shown in Table 3. Specifically, Lys-C digestion yields 387 
MMQAHINPVFDPAEDGKEASARGARPSVSGALDPK (NCC1/2 res 785-820, Andromeda 388 
score 49.2) and MMQAHINPVFDPAEDGKEASARVDPK (NCC3 res 785-811, Andromeda 389 
score 70.3), as well as EASARGARPSVSGALDPK (NCC1/2 res 802-820, Andromeda 390 
score 57.5) and EASARVDPKALVK (NCC3 res 802-815, Andromeda score 32.9). Tryptic 391 
digestion additionally yielded GARPSVSGALDPK (NCC1/2 res 807-820, Andromeda score 392 
122.5) and PSVSGALDPK (NCC1/2 res 810-820, Andromeda score 104.8). Identification of 393 
multiple overlapping peptides of both NCC3 as well as NCC1/2 firmly indicated that in 394 
exosomes, the SCL12A3 gene product is present as a mixture of NCC3 and at least one 395 
and possibly both NCC1 and NCC2. 396 
 397 
Generation of specific antibodies against NCC1/2 398 
NCC1/2-specific peptide epitope (ARGARPSVSGALDP) was used to generate anti-NCC1/2 399 
antibodies. Specificity of the antibody was tested using isolated membranes from HEK293 400 
cells transfected with corresponding plasmids. A commercially available antibody against 401 
the N-terminal portion of NCC detected NCC3 as well as NCC1/2, as all are carrying the 402 
recognized epitope (Fig. 2A). Therefore, in the present study expression of NCC, detected 403 
by the antibody against the N-terminal NCC, refers to the combined expression of NCC3 404 
and NCC1/2 hence denoted as NCC1-3. The antibody specific for NCC1/2 recognized only 405 
NCC1/2, but not NCC3 and NCC1/2 mutants (S811A and S811D) (Fig. 2B). This 406 
demonstrates the high specificity of the newly generated antibody against the NCC1/2 407 
epitope. Immunoreactivity was not present in cells transfected with mock vector or in the 408 
presence of specific blocking peptides (Fig. 2C). 409 
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 410 
Immunoblot identification of human NCC isoforms 411 
Immunoblots of kidney membrane fractions and urinary exosomes of three subjects 412 
showed two immunopositive protein bands of approximately 260 and 130 kDa, 413 
representing the dimeric and monomeric form of the NCC1-3 transporter, respectively (Fig. 414 
2D). Importantly, the NCC1/2 protein was also detected in kidney membrane fractions and 415 
urinary exosomes as two bands of approximately 260 and 130 kDa as evidence for the 416 
dimeric and monomeric form, respectively (Fig. 2E). This indicates that NCC isoforms are 417 
present in oligomeric structures in the human kidney and urinary exosomes. 418 
 419 
NCC1/2 localizes to apical membrane of DCT 420 
Immunohistochemical staining of human kidney serial sections revealed expression of 421 
NCC1-3 (Fig. 3A and B) and NCC1/2 (Fig. 3C and D) at the apical membrane of epithelial 422 
cells lining the DCT. Expression of both NCC1-3 and NCC1/2 was restricted to the same 423 
tubular sites.  424 
 425 
Functional characterization of NCC1 426 
In order to compare the functional abilities of NCC1 and NCC3, cRNA of the respective 427 
variants was microinjected into Xenopus laevis oocytes and thiazide-sensitive 22Na+ 428 
uptake was measured (Fig. 4). It has been shown previously that cumulative amounts of 429 
eGFP-NCC correlate dose-dependently with the eGFP-NCC fluorescence at the oocyte 430 
membrane and with thiazide-sensitive 22Na+ uptake (7). For the analysis, day 4 after cRNA 431 
injection was chosen. Thiazide-sensitive 22Na+ transport was significantly increased in the 432 
NCC1 compared to the NCC3 (Fig. 4A). To further evaluate whether this increase in 433 
transport was dependent on the phosphorylation at S811 the effect of substituting the 434 
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serine residue by an aspartic acid to mimic constitutive phosphorylation was tested. The 435 
S811D mutant exhibited a significant increase in thiazide-sensitive 22Na+ uptake in 436 
comparison to NCC3 and NCC1. Moreover, the S811A mutant mimicking a constitutively 437 
inactive phosphorylation site showed a significant decrease in thiazide-sensitive 22Na+ 438 
uptake, as compared to NCC1 S811D variants (Fig. 4A).  439 
 440 
WNK4 has previously been shown to reduce forward trafficking of NCC in the oocyte 441 
system, by diverting the cotransporter to the lysosomal compartment (38, 49). Additionally, 442 
WNK 4 modulates SPAK/OSR1 phosphorylation and hence NCC activity (4, 43). To 443 
elucidate whether WNK4 has similar effects on NCC1, cRNA encoding the NCC variants 444 
were co-injected with WNK4. WNK4 reduced NCC-dependent 22Na+ uptake to similar 445 
levels in all conditions, suggesting that the majority of NCC1 activity is sensitive to WNK4 446 
inhibition in S811 independent manner (Fig. 4A). In each condition 22Na+ uptake was 447 
thiazide-sensitive (Fig. 4A, black bars). To determine surface expression of injected cRNA, 448 
fluorescent intensity of eGFP-tagged NCC3, NCC1, NCC1 S811D or NCC1 S811A was 449 
quantified (Fig. 4B and C). 450 
 451 
Acute water loading 452 
Acute water loading was performed in six healthy subjects to determine the effect of 453 
hypervolemia on the renal expression of NCC isoforms. Urine was collected before (time 454 
0) and after acute water loading in 30-minute intervals up to 150 minutes. Urinary 455 
exosomes of each subject were loaded according to the urine creatinine concentration 456 
onto the gel and to confirm equal loading of the samples, the abundance of the exosomal 457 
marker CD9 was determined (1, 11). Our study demonstrated the existence of NCC in 458 
dimeric and monomeric forms in urinary exosomes using immunoblotting. Therefore, both 459 
dimeric and monomeric forms were analyzed separately. Immunoblots probed for NCC1/2 460 
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showed a significant decrease of NCC1/2 monomer and dimer expression 60 minutes after 461 
acute water loading, which returned to the baseline levels at 150 minutes (Fig. 5A, C and 462 
E). Expression of NCC1-3 monomer and dimer significantly dropped 60 minutes after acute 463 
water loading and restored after 150 minutes (Fig. 5B, D and F). The exosomes were also 464 
probed for the expression of aquaporin 2 (AQP2) since water loading is known to 465 
downregulate AQP2 (36). Indeed, AQP2 expression in urinary exosomes was significantly 466 
reduced 60 minutes after acute water loading (Fig. 6A and B). CD9 expression levels 467 
within urinary exosomes did not change significantly at different time points, suggesting 468 
equal loading of exosomes (Fig. 5G, 5H, 6C, respectively). Urine osmolality decreased 469 
significantly 30 minutes after acute water loading (Fig. 6D). 470 
 471 
DISCUSSION  472 
Since 1996, when human NCC was cloned, it has been shown that three isoforms of NCC 473 
are present in the human kidney (22, 23, 35). However, all NCC studies have focused on 474 
the shorter isoform, NCC3, leaving the alternative splice variants unexplored. In the 475 
presented study, we delineated for the first time the localization, abundance, and 476 
functionality of NCC1/2 in the human kidney by showing that: i) mRNA of NCC1/2 constitutes 477 
approximately 44% of all NCC (NCC1-3) transcripts in the human kidney; ii) NCC1/2 is 478 
clearly detectable in human urinary exosomes by mass spectrometry and immunoblot 479 
analysis; iii) NCC1/2 is, like the shorter NCC3 isoform, present at the apical membrane of 480 
DCT; iv) phosphorylation at S811 regulates NCC1 function; v) the abundance of NCC1/2 is 481 
regulated in response to physiological stimuli such as acute water loading. 482 
 483 
Generation of new antibodies specifically recognizing NCC1/2 allowed us to demonstrate 484 
the presence of NCC1/2 at the apical membrane of the DCT, present in the human kidney 485 
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as well as monomeric and dimeric complexes in kidney membrane fractions and urinary 486 
exosomes. The presence of NCC1/2 in the exosomes was confirmed by mass 487 
spectrometry. Noteworthy, all antibodies raised against NCC3 recognize also NCC1/2. 488 
Thus, in previously performed studies on endogenous human NCC also NCC1/2 may have 489 
been detected. Because human NCC1 and NCC2 differ only by one amino acid it was 490 
impossible to differentiate between both isoforms with the immunodetection methods. 491 
Therefore, it was addressed as a combined expression of both isoforms, NCC1/2. We 492 
demonstrated that NCC1/2 mRNA constitutes a substantial amount (44%) of total NCC 493 
mRNA in the human kidney. Nevertheless, the relative protein abundance of each isoform 494 
depends on the translation and quality control of the proteins. Therefore, the expression 495 
level of mRNA does not always mirror the abundance of the protein. Moreover, presented 496 
mRNA analysis characterizes a combined expression of NCC1 and NCC2 since they were 497 
indistinguishable. Hence, the ratio of each isoform is not strictly determined.  498 
 499 
Functional characterization of NCC1 and the role of its phosphorylation site S811 were 500 
investigated by using Xenopus oocytes. As NCC3, NCC1 demonstrated thiazide-sensitive 501 
22Na+ transport. Additionally, NCC1 activity can also be modified by changes in 502 
phosphorylation status. Splicing and subsequent single point directed mutagenesis to 503 
mimic constitutively active phosphorylation sites of NCC1 (S811D) led to an increased 504 
activity of NCC1 compared to NCC3. We demonstrated that once the S811 residue is 505 
substituted by an alanine (S811A) mimicking inactive site, the activity of the splice variant 506 
is significantly decreased. The fact that inhibition of S811 phosphorylation reverts 507 
transporter capability only to basal levels implies that the NCC1/2 and its phosphorylation is 508 
introduced in order to augment transport of NCC over the baseline level when needed. Our 509 
functional experiments demonstrated that WNK4 is a strong inhibitor of both NCC1 and 510 
NCC3. However, the effect of WNK4 is not mediated via S811 phosphorylation, since the 511 
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constitutively active S811D mutant is not protected from the inhibitory effects of WNK4. 512 
This suggests that in both isoforms, NCC1 and NCC3, the effect of WNK4 is mediated via 513 
regulation at the N-terminus. Additionally, phosphorylation at S811 may depend on 514 
simultaneous regulation of the phosphorylation at the N-terminal residues.  515 
 516 
In order to determine NCC1/2 expression in vivo, human urinary exosomes were analyzed. 517 
Exosomes are frequently used as biomarkers for renal tubular disorders as they reflect 518 
changes in the expression of different proteins present in the tubular epithelial cells (16, 519 
40). For instance, it has been demonstrated that patients with Gitelman syndrome do not 520 
express NCC in their urinary exosomes (19). In contrast, patients with familial 521 
hyperkalemic hypertension characterized by enhanced activity of NCC, have increased 522 
NCC expression in their urinary exosomes (17, 24). This substantiates the notion that NCC 523 
abundance in urinary exosomes reflects the actual state of NCC expression in the DCT as 524 
postulated previously (16, 40). We hypothesized that the activity of NCC1/2 can be modified 525 
by changes in the protein abundance at the plasma membrane. Depending on a stimulus 526 
(hormones, electrolyte concentration, etc.) NCC expression throughout the DCT can be 527 
altered by the insertion of a more potent isoform (NCC1/2) into the apical membrane, in 528 
order to maximize NaCl transport and vice versa. Consequently, we showed that NCC1/2 529 
and NCC1-3 abundance in urinary exosomes is robustly down regulated in response to 530 
water loading (Fig. 5). Increased activity and expression of NCC in response to changes in 531 
the renin-angiotensin-aldosterone system and vasopressin has been well documented (5, 532 
28, 30-34, 41, 42). Hence, decreased NCC abundance at the apical plasma membrane in 533 
water-loaded subjects is likely a result of hypervolemia, hyponatremia, and a subsequent 534 
decline in vasopressin release.  535 
 536 
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Thus far, signaling pathways regulating NCC1/2 are unknown. However, prediction software 537 
(pkaPS) from the IMP-IMBA Bioinformatics group (26) suggested that the phosphorylated 538 
sequence around S811 of NCC1/2 shows high similarity to a PKA consensus site. 539 
Therefore, potential hormones regulating the cAMP-PKA pathway might be involved in 540 
regulating transport via this kinase. Several hormonal systems have been shown to 541 
activate the cAMP-PKA pathway in the DCT (3, 9). Our water loading study substantiates 542 
the regulatory effect of vasopressin not only on NCC1-3 but also specifically on NCC1/2 543 
abundance in the kidney. Since S811 may contain PKA consensus site we hypothesized 544 
that a PKA-dependent mechanism could be occurring for the phosphorylation at S811 in 545 
response to vasopressin stimulation. Nevertheless, recent studies demonstrated a 546 
potential role for vasopressin in modulating NCC N-terminal phosphorylation in the DCT 547 
(25, 28, 34), which may constitute the main regulatory mechanism for all NCC isoforms 548 
since all variants contain the same N-terminal phosphorylation sites. 549 
 550 
Our data clearly demonstrates that NCC1/2 is not a redundant transcription product, but it 551 
merely constitutes a fully functional thiazide-sensitive NaCl-transporting protein. In parallel, 552 
we propose a novel way of NCC regulation by phosphorylation at the C-terminal S811 553 
residue that adds to the complex system governing the regulation of NCC. Future 554 
experiments developing S811 phospho-specific antibodies and samples from different 555 
human pathological states could aid in determining the precise regulation of NCC1/2. A 556 
better understanding of the regulation of NCC in the kidneys may be critical to help to 557 
elucidate the molecular events underlying the pathogenesis of essential hypertension.558 
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FIGURE LEGENDS 764 
Figure 1. Splicing of NCC gene. (A) Multiple protein alignment analysis of NCC against 765 
diverse species as stated. (B) Schematic representation of gene SLC12A3 and the exon 766 
20a, in light grey box, that encodes for the splice variant. (C) DNA multiple alignment and 767 
chromatogram sequence analysis of the region encoding the human NCC1/2 and NCC3. (D) 768 
Topological representation of NCC1/2 within the N-terminal domain, in light grey shadow, 769 
shows alignment of all three human NCC isoform sequences (NCC3, NCC2, and NCC1) 770 
and carboxyl-terminal domain, in light grey shadow, shows the phosphorylation site at 771 
S811. Lower panel shows a multiple alignment of the human NCC protein sequence 772 
depicted the additional nine amino acids in NCC1/2, including the phosphorylation mutant 773 
constructs (S811D and S811A). 774 
 775 
Figure 2. Verification of NCC1/2 antibody specificity. (A) Immunoblot of total membrane 776 
fraction isolated from HEK293 cells transfected with empty vector (mock), NCC3, NCC1 777 
and NCC1 phosphorylation site mutants (S811A and S811D) probed with an antibody 778 
against NCC1-3. (B) Immunoblot of total membrane fraction isolated from HEK293 cells 779 
transfected with empty vector (mock), NCC3, NCC1, and NCC1 mutants (S811A and 780 
S811D) probed with an antibody recognizing specifically NCC1/2. (C) Immunoblot of total 781 
membrane fraction isolated from HEK293 cells transfected with empty vector (mock), 782 
NCC3, NCC1 and NCC1 mutants (S811A and S811D) probed with the NCC1/2 antibody pre-783 
absorbed with NCC1/2 immunizing peptide. (D) Expression of NCC1-3 and (E) NCC1/2 in 784 
kidney membrane fractions and urinary exosomes of three subjects depicting two bands of 785 
approximately 260 and 130 kDa. 786 
 787 
 788 
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Figure 3. Immunolocalization of NCC1/2 in the human kidney. Representative serial 789 
sections of human kidney depicting NCC1-3 (A and B) and NCC1/2 (C and D). 790 
Immunofluorescence colocalizes at the apical membrane domains of epithelial cells lining 791 
DCT. As the antibody against NCC1-3 also binds to NCC1/2, immunofluorescence in A and 792 
B may partially originate from NCC1/2. The bar represents a scale of 20 or 50 m as 793 
indicated. 794 
 795 
Figure 4. Expression and functional analysis of eGFP tagged NCC variants in the 796 
oocyte membrane. (A) 22Na+ uptakes in Xenopus laevis oocytes microinjected with 5 ng 797 
of cRNA encoding the human NCC3, NCC1, NCC1 S811D, NCC1 S811A or co-injected with 798 
10 ng of WNK4 cRNA. The 22Na+ uptake experiments were performed in the absence 799 
(white bars) or presence (black bars) of 0.1 mM HCT. 22Na+ uptakes were corrected for 800 
surface expression of the corresponding variants. NCC1 vs. NCC3 (§) as well as NCC1 801 
S811D vs. NCC1 (#) had significantly increased 22Na+ uptake. NCC1 S811A had 802 
significantly reduced 22Na+ uptake in comparison to NCC1 S811D (†). Each variant co-803 
injected with WNK4 had significantly decreased 22Na+ uptake in comparison to its 804 
corresponding variant without WNK4 (*). (B) Three representative confocal images of 805 
oocytes that were injected with GFP-NCC3, GFP-NCC1, GFP-NCC1 S811D or GFP-NCC1 806 
S811A cRNA. (C) Surface expression analyses were performed on oocytes four days after 807 
microinjection with corresponding cRNA. *P<0.05 was considered statistically significant. 808 
 809 
Figure 5. Expression of NCC1/2 and NCC1-3 in human urinary exosomes after acute 810 
water loading. Immunoblot of urinary exosomes isolated before (0 minute) and after water 811 
loading probed for NCC1/2 (A) and NCC1-3 (B). Both NCC1/2 and NCC1-3 abundance was 812 
significantly reduced 60 minutes after acute water loading and returned to the baseline 813 
level after 150 minutes. Densitometry analysis of NCC1/2 (C) and NCC1-3 (D) monomer 814 
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abundance in urinary exosomes. Densitometry analysis of NCC1/2 (E) and NCC1-3 (F) 815 
dimer abundance in urinary exosomes. (G and H) Densitometry analysis of CD9 816 
expression levels showed no significant changes. Values are mean ± SEM (n = 6) 817 
normalized to time 0 levels. *P<0.05 was considered significant. 818 
 819 
Figure 6. Expression of AQP2 in human urinary exosomes after acute water loading.  820 
(A) Immunoblot of urinary exosomes isolated before (0 minute) and after water loading 821 
probed for AQP2. AQP2 abundance was significantly decreased 60 minutes after acute 822 
water loading and maintained significantly lower levels up to 150 minutes. (B) 823 
Densitometry analysis of AQP2 abundance in urinary exosomes. (C) Densitometry 824 
analysis of CD9 expression levels corrected to urine creatinine concentration showed no 825 
significant changes. (D) Urinary osmolality was significantly decreased from 30 to 150 826 
minutes after acute water loading. Values are mean ± SEM (n = 6) normalized to time 0 827 
minute levels. *P<0.05 was considered significant. 828 
829 
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TABLES 830 
Table 1. Ratio of NCC1/2 to NCC1-3 mRNA expression in seven human kidney cortex 831 
biopsies determined by Real-time relative RT-PCR quantification. 832 
833 Volunteer # % NCC1/2 
1 52 
2 46 
3 19 
4 29 
5 42 
6 59 
7 63 
  
Average % 44 
SEM ± 6 
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Table 2. Identified SCL12A3 peptides in urinary exosomes of healthy subjects. 834 
Sequence Identified Peptide Length 
Missed 
cleavages Proteins 
Start 
position 
End 
position 
Gene 
names 
Charg
es PEP Score 
MS/MS 
Count Protease
Isof
orm
AELPTTETPGDATLCSGR 18 0 P55017-2;P55017-3;P55017;J3QSS1 2 19 SLC12A3 2;3 1,85E-17 118,48 12 Trypsin all 
FTISTLLSSDEPSPPAAYDSSHP
SHLTHSSTFCMR 35 0 
P55017-2;P55017-
3;P55017;J3QSS1 20 54 SLC12A3 5 6,21E-14 74,282 2 Trypsin all 
TFGYNTIDVVPTYEHYANSTQP
GEPR 26 0 
P55017-2;P55017-
3;P55017;J3QSS1 55 80 SLC12A3 3;4 2,23E-94 234,73 14 Trypsin all 
KVRPTLADLHSFLK 14 2 P55017-2;P55017-3;P55017;J3QSS1 81 94 SLC12A3 3;4 4,60E-23 172,85 32 Trypsin all 
VRPTLADLHSFLK 13 1 P55017-2;P55017-3;P55017;J3QSS1 82 94 SLC12A3 3;4 1,72E-16 145,43 24 Trypsin all 
VRPTLADLHSFLK 13 0 J3QSS1;P55017;P55017-3;P55017-2 82 94 SLC12A3 2;3;4 4,08E-33 176,89 37 Lys-C all 
HLHALAFDSR 10 0 P55017-2;P55017-3;P55017;J3QSS1 99 108 SLC12A3 2;3 1,72E-15 183,72 18 Trypsin all 
HLHALAFDSRPSHEMTDGLVE
GEAGTSSEK 30 1 
P55017-2;P55017-
3;P55017;J3QSS1 99 128 SLC12A3 5 1,60E-23 113,91 7 Trypsin all 
HLHALAFDSRPSHEMTDGLVE
GEAGTSSEKNPEEPVR 37 2 
P55017-2;P55017-
3;P55017;J3QSS1 99 135 SLC12A3 6 2,19E-21 102,47 3 Trypsin all 
PSHEMTDGLVEGEAGTSSEK 20 0 P55017-2;P55017-3;P55017;J3QSS1 109 128 SLC12A3 3 7,77E-19 117,29 8 Trypsin all 
PSHEMTDGLVEGEAGTSSEKN
PEEPVR 27 1 
P55017-2;P55017-
3;P55017;J3QSS1 109 135 SLC12A3 4 3,95E-22 114,9 5 Trypsin all 
VKSGGTYFLISR 12 1 P55017-2;P55017-3;P55017;J3QSS1 198 209 SLC12A3 2;3 1,00E-05 90,614 8 Trypsin all 
SGGTYFLISR 10 0 P55017-2;P55017-3;P55017;J3QSS1 200 209 SLC12A3 2;3 1,12E-15 189,58 7 Trypsin all 
DPAIAIPK 8 0 P55017-2;P55017-3;P55017;J3QSS1 366 373 SLC12A3 2 2,15E-02 67,464 2 Trypsin all 
NYRPQCLVLTGPPNFR 16 1 P55017-2;P55017-3;P55017;J3QSS1 640 655 SLC12A3 3 5,60E-02 27,488 1 Trypsin all 
MPELQLIANGHTK 13 0 P55017-2;P55017-3;P55017;J3QSS1 686 698 SLC12A3 2;3 1,71E-36 214,46 24 Trypsin all 
IKAFYSDVIAEDLR 14 1 P55017-2;P55017-3;P55017;J3QSS1 705 718 SLC12A3 3 4,11E-04 55,815 3 Trypsin all 
IKAFYSDVIAEDLRR 15 2 P55017-2;P55017-3;P55017;J3QSS1 705 719 SLC12A3 3;4 5,75E-18 132,08 16 Trypsin all 
AFYSDVIAEDLR 12 0 P55017-2;P55017-3;P55017;J3QSS1 707 718 SLC12A3 2;3 1,81E-14 129,34 5 Trypsin all 
AFYSDVIAEDLRR 13 1 P55017-2;P55017-3;P55017;J3QSS1 707 719 SLC12A3 3 2,76E-23 179,35 7 Trypsin all 
RGVQILMQAAGLGR 14 1 P55017-2;P55017-3;P55017;J3QSS1 719 732 SLC12A3 3 2,67E-10 111,79 4 Trypsin all 
GVQILMQAAGLGR 13 0 P55017-2;P55017-3;P55017;J3QSS1 720 732 SLC12A3 2;3 3,70E-36 213,63 26 Trypsin all 
MKPNILVVGFK 11 1 P55017-2;P55017-3;P55017;J3QSS1 733 743 SLC12A3 2;3 9,29E-10 128,81 20 Trypsin all 
MKPNILVVGFKK 12 2 P55017-2;P55017-3;P55017;J3QSS1 733 744 SLC12A3 2;3 1,78E-05 90,913 10 Trypsin all 
MREGLNVSK 9 1 P55017-2;P55017-3;P55017;J3QSS1 776 784 SLC12A3 2;3 1,57E-03 108,47 5 Trypsin all 
MMQAHINPVFDPAEDGK 17 0 J3QSS1;P55017;P55017-3;P55017-2 784 800 SLC12A3 2;3 1,26E-07 95,197 18 Lys-C all 
MMQAHINPVFDPAEDGKEASA
RGARPSVSGALDPK 35 1 P55017-3;P55017-2 784 818 SLC12A3 5;6 2,62E-08 49,209 7 Lys-C 2,3
MMQAHINPVFDPAEDGKEASA
RVDPK 26 1 J3QSS1;P55017 784 809 SLC12A3 3;4;5 2,25E-09 70,316 13 Lys-C 1 
MMQAHINPVFDPAEDGK 17 0 P55017-2;P55017-3;P55017;J3QSS1 785 801 SLC12A3 2;3 3,37E-14 117,18 15 Trypsin all 
MMQAHINPVFDPAEDGKEASA
R 22 1 
P55017-2;P55017-
3;P55017;J3QSS1 785 806 SLC12A3 3;4 5,19E-28 130,19 33 Trypsin all 
EASARGARPSVSGALDPK 18 0 P55017-3;P55017-2 801 818 SLC12A3 4 7,16E-05 57,525 7 Lys-C 2,3
EASARVDPKALVK 13 1 J3QSS1;P55017 801 813 SLC12A3 3 1,93E-02 32,933 1 Lys-C 1 
EASARGARPSVSGALDPK 18 2 P55017-2;P55017-3 802 819 SLC12A3 4 2,65E-03 42,633 1 Trypsin 2,3
GARPSVSGALDPK 13 1 P55017-2;P55017-3 807 819 SLC12A3 2;3 2,65E-10 122,46 8 Trypsin 2,3
PSVSGALDPK 10 0 P55017-2;P55017-3 810 819 SLC12A3 2 1,87E-04 104,82 4 Trypsin 2,3
ALVKEEQATTIFQSEQGK 18 1 J3QSS1;P55017;P55017-3;P55017-2 810 827 SLC12A3 2;3 4,54E-36 161,91 9 Lys-C all 
ALVKEEQATTIFQSEQGKK 19 2 J3QSS1;P55017;P55017-3;P55017-2 810 828 SLC12A3 2;3;4 2,34E-45 176,69 10 Lys-C all 
EEQATTIFQSEQGK 14 0 J3QSS1;P55017;P55017-3;P55017-2 814 827 SLC12A3 2;3 2,96E-87 249,19 12 Lys-C all 
EEQATTIFQSEQGKK 15 1 J3QSS1;P55017;P55017-3;P55017-2 814 828 SLC12A3 2;3 1,29E-09 120,92 7 Lys-C all 
ALVKEEQATTIFQSEQGK 18 1 P55017-2;P55017-3;P55017;J3QSS1 820 837 SLC12A3 2;3 5,66E-46 182,76 7 Trypsin all 
ALVKEEQATTIFQSEQGKK 19 2 P55017-2;P55017-3;P55017;J3QSS1 820 838 SLC12A3 2;3;4 9,16E-57 217,97 16 Trypsin all 
EEQATTIFQSEQGK 14 0 P55017-2;P55017-3;P55017;J3QSS1 824 837 SLC12A3 2;3 7,10E-36 209,19 5 Trypsin all 
Splice variant of the NaCl cotransporter 
 
34 
835 
EEQATTIFQSEQGKK 15 1 P55017-2;P55017-3;P55017;J3QSS1 824 838 SLC12A3 2;3 2,34E-30 176,4 13 Trypsin all 
IRVFVGGQINR 11 1 P55017-2;P55017-3;P55017;J3QSS1 870 880 SLC12A3 3 5,75E-04 70,412 1 Trypsin all 
VFVGGQINR 9 0 P55017-2;P55017-3;P55017;J3QSS1 872 880 SLC12A3 2 3,27E-05 143,61 6 Trypsin all 
AIISLLSK 8 0 J3QSS1;P55017;P55017-3;P55017-2 877 884 SLC12A3 2 2,43E-02 67,897 1 Lys-C all 
FRLGFHEVHILPDINQNPRAEHT
K 24 0 
J3QSS1;P55017;P5
5017-3;P55017-2 885 908 SLC12A3 5;6 1,19E-09 90,978 3 Lys-C all 
KAIISLLSK 9 1 P55017-2;P55017-3;P55017;J3QSS1 886 894 SLC12A3 2 6,67E-05 138,25 7 Trypsin all 
AIISLLSK 8 0 P55017-2;P55017-3;P55017;J3QSS1 887 894 SLC12A3 2 9,65E-03 77,732 6 Trypsin all 
FRLGFHEVHILPDINQNPR 19 1 P55017-2;P55017-3;P55017;J3QSS1 895 913 SLC12A3 4;5 1,34E-12 96,447 5 Trypsin all 
LGFHEVHILPDINQNPR 17 0 P55017-2;P55017-3;P55017;J3QSS1 897 913 SLC12A3 2;3;4 1,25E-19 138,01 21 Trypsin all 
RFEDMIAPFRLNDGFK 16 0 J3QSS1;P55017;P55017-3;P55017-2 909 924 SLC12A3 3;4 4,08E-05 71,354 14 Lys-C all 
RFEDMIAPFRLNDGFKDEATVN
EMRRDCPWK 31 1 
J3QSS1;P55017;P5
5017-3;P55017-2 909 939 SLC12A3 5;6 2,91E-08 58,087 9 Lys-C all 
RFEDMIAPFR 10 1 P55017-2;P55017-3;P55017;J3QSS1 919 928 SLC12A3 2;3 1,16E-05 115,78 24 Trypsin all 
RFEDMIAPFRLNDGFK 16 2 P55017-2;P55017-3;P55017;J3QSS1 919 934 SLC12A3 3;4 3,02E-03 44,998 2 Trypsin all 
FEDMIAPFR 9 0 P55017-2;P55017-3;P55017;J3QSS1 920 928 SLC12A3 2;3 1,09E-04 128,36 16 Trypsin all 
DEATVNEMRRDCPWK 15 0 J3QSS1;P55017;P55017-3;P55017-2 925 939 SLC12A3 3 3,97E-05 79,875 2 Lys-C all 
LNDGFKDEATVNEMR 15 1 P55017-2;P55017-3;P55017;J3QSS1 929 943 SLC12A3 2;3 3,93E-45 212,5 20 Trypsin all 
LNDGFKDEATVNEMRR 16 2 P55017-2;P55017-3;P55017;J3QSS1 929 944 SLC12A3 3;4 6,44E-31 178,01 16 Trypsin all 
ISDEEITK 8 0 J3QSS1;P55017;P55017-3;P55017-2 940 947 SLC12A3 2 4,81E-05 130,56 6 Lys-C all 
ISDEEITKNRVK 12 1 J3QSS1;P55017;P55017-3;P55017-2 940 951 SLC12A3 2;3;4 6,39E-28 177,1 18 Lys-C all 
ISDEEITK 8 0 P55017-2;P55017-3;P55017;J3QSS1 950 957 SLC12A3 2 1,67E-03 122,44 5 Trypsin all 
ISDEEITKNR 10 1 P55017-2;P55017-3;P55017;J3QSS1 950 959 SLC12A3 2 1,89E-04 112,13 2 Trypsin all 
ISDEEITKNRVK 12 2 P55017-2;P55017-3;P55017;J3QSS1 950 961 SLC12A3 2;3;4 7,93E-09 132,14 3 Trypsin all 
LNEIVLDYSR 10 0 P55017-2;P55017-3;P55017;J3QSS1 968 977 SLC12A3 2;3 6,63E-16 193,96 12 Trypsin all 
DAALIVITLPIGRK 14 1 P55017-2;P55017-3;P55017;J3QSS1 978 991 SLC12A3 3 8,36E-06 75,764 3 Trypsin all 
GNQENVLTFYCQ 12 0 P55017-2;P55017-
3;P55017;J3QSS1 
1019 1030 SLC12A3 2;3 1,16E-09 128,57 8 Trypsin all 
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Table 3. Peptides identified from the isoform-specific region of SLC12A3 aligned to 836 
the protein amino acid sequence. In red NCC3 specific residues and in green NCC1/2 837 
specific residues. In the middle the aligned amino acid sequences of  838 
NCC3 and NCC1/2. 839 
 840 
Isoform Nomen-
clature 
Protease Sequence of identified peptides 
  Lys-C                                                                                             811/820ALVKEEQATTIFQSEQGK829/838 
  Lys-C           785MMQAHINPVFDPAEDGK802 
  Lys-C           785MMQAHINPVFDPAEDGKEASAR −−−−−−−−−−− VDPK811 
  Lys-C                                                               802EASAR −−−−−−−−−−−VDPKALVK815 
SLC12A3-3 NCC3  781NVSKMMQAHINPVFDPAEDGKEASAR −−−−−−−−−−−  VDPKALVKEEQATTIFQSEQGK829 
SLC12A3-1/2 NCC1/2  781NVSKMMQAHINPVFDPAEDGKEASARGARPSVSGALDPKALVKEEQATTIFQSEQGK838 
  Trypsin               785MMQAHINPVFDPAEDGKEASAR807 
  Lys-C               785MMQAHINPVFDPAEDGKEASARGARPSVSGALDPK820 
  Trypsin                                                        802EASARGARPSVSGALDPK820 
  Trypsin                                                                      807GARPSVSGALDPK820 
  Trypsin                                                                            810PSVSGALDPK820 






